Tapentadol-β-D-glucuronide is the primary urinary metabolite of tapentadol, the first new drug of the centrally-acting analgesic class approved in the US for pain management in more than 25 years. This new internal standard is suitable for many LC/MS or GC/MS applications including pain prescription monitoring, forensic testing, clinical toxicology, urine drug testing or isotope dilution methods.